Initiate Part 2 and Part 3 of the INBRX-106 clinical trial
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 5 Jan 2021
- Due
- 31 Jan 2021
- Delivered
- February 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Part 2 (single-agent expansion) and Part 3 (combination dose escalation) of the trial will both be initiated this month.”
What we found
Evidence strength A What the grades mean
The company announced in January 2021 that it would initiate Part 2 and Part 3 of the INBRX-106 trial that month, but later filings confirmed these parts were initiated in February 2021.
-
A Inhibrx, Inc. 10-K filed 2021-03-12
“Part 2 of this trial, single-agent dose expansion, and Part 3 of this trial, dose escalation in combination with Keytruda, were both initiated in February 2021.” ✓ confirmed on the page
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Initiate
- Deliverable
- Part 2 and Part 3 of the INBRX-106 trial
- Language
- Firm (“will”, “on track to”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Inhibrx, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C739614-021094 · Corrections policy